Improving the gastrointestinal safety of NSAIDs: The development of misoprostol - From hypothesis to clinical practice

Digestive Diseases and Sciences

Volumn 43, Issue 3, 1998, Pages 447-458

  Silverstein, Fred E ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

Mucosal cytoprotection; NSAIDs; Prostaglandins; Ulcer; Ulcer complication

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E1 DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ALZHEIMER DISEASE; ARTHRITIS; COLON CANCER; DRUG MECHANISM; DRUG SAFETY; DUODENUM ULCER; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS; DICLOFENAC; DRUG COMBINATIONS; HISTORY, 20TH CENTURY; HUMANS; MISOPROSTOL; PEPTIC ULCER;

EID: 0031970141     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018895417831     Document Type: Review

References (82)

1. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA 272:65-69, 1994
2. Graham DY, Lew GM, Klein PD, et al: Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 116:705-708, 1992
3. Davenport HW: Salicylate damage to the gastric mucosal barrier. N Engl J Med 267:1307-1312, 1967
4. Smith JL, Graham DY, Dobbs SM: Time course, extent and duration of acute aspirin injury to the stomach of man. Gastrointest Endosc 27:129, 1981 (abstract)
5. Konturek SJ, Ohtulowicz W, Sito E, et al: Distribution of prostaglandins in gastric and duodenal mucosa of healthy subjects and duodenal ulcer patients: Effect of aspirin and paracetamol. Gut 22:283-289, 1981
6. Lanza FL, Royer GL, Nelson RS: Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 303:136-138, 1980
7. Silvoso GR, Ivey KJ, Butt JH, et al: Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 91:517-520, 1979
8. Lockard OO, Ivey KJ, Butt JH, Silvoso GR, Sisk C, Holt S: The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy. Gastrointest Endosc 26:5-7, 1980
9. Robinson MG, Griffin JW, Bowers J, et al: Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 34:424-428, 1989
10. Larkai EN, Smith JL, Lidsky MD, Graham DY: Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82:1153-1158, 1987
11. Graham DY, Agrawal NM, Roth S: Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial. Lancet 2:1277-1280, 1988
12. Farah D, Sturrock RD, Russell RI: Peptic ulcer in rheumatoid arthritis. Ann Rheum Dis 47:478-480, 1988
13. Ehsanullah RSB, Page MD, Tildesley G, Wood JR: Prevention of gastroduodenal damage induced by nonsteroidal antiinflammatory drugs: controlled trial with ranitidine. BMJ 297:1017-1021, 1988
14. Lichtenstein DR, Syngal S, Wolfe MM: Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: The double-edged sword. Arthritis Rheum 38:5-18, 1995
15. Aspirin Myocardial Infarction Study Research Group: A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243:661-669, 1980
16. Armstrong CP, Blower AL: Non-steroidal anti-inflammatory drugs and life threatening complication of peptic ulceration. Gut 28:527-532, 1987
17. Graham DY, Smith JL: Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol 83:1081-1084, 1988
18. Labeling revisions for NSAIDs. FDA Drug Bull 19:3-4, 1989
19. Fries JF: NSAID gastropathy: Epidemiology. J Musculoskel Med 8:21-28, 1991
20. Fries JF: NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 18(suppl 28):6-10, 1991
21. Paulus HE: FDA arthritis advisory committee meeting: Post-marketing surveillance of non-steroidal anti-inflammatory drugs. Arthritis Rheum 28:1168-1169, 1985
22. Soll AH, Weinstein WM, Kurata J, McCarthy D: Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 114:307-319, 1991
23. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML: Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: A case-control study. Gut 32:730-734, 1991
24. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis. Ann Intern Med 115:787-796, 1991
25. Ivey KJ: Gastrointestinal intolerance and bleeding with non-narcotic analgesics. Drugs 32(suppl 4):71-89, 1986
26. Hoftiezer JW, Silvoso GR, Burks M, Ivey KJ: Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet 2:609-612, 1980
27. Langman MJS, Well J, Wainwright P, et al: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075-1078, 1994
28. Meade EA, Smith WL, Dewitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 268:6610-6614, 1993
29. Patrignani P, Panara MR, Greco A, et al: Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 217:1705-1712, 1994
30. Roth SH, Tindall EA, Jain AK, et al: A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract. Arch Intern Med 153:2565-2571, 1993
31. Inman HW, Wilton LV, Pearce GL, Waller PC: Prescription-event monitoring of nabumetone. Pharm Med 4:309-317, 1990
32. Graham DY: Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastroenterology 96:675-681, 1989
33. Robert A, Nezamis JE, Lancaster C, et al: Gastric cytoprotective property of prostaglandins. Gastroenterology 72:1121, 1977
34. Robert A, Nezamis JE, Lancaster C, Hanchar AJ: Cytoprotection by prostaglandins in rats: Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl and thermal injury. Gastroenterology 77(3):433-443, 1979
35. Robert A: Cytoprotection by proslaglandins. Gastroenterology 77:761-766, 1979
36. Rees WDW, Shorrock CJ: Overview of gastroduodenal mucosal protection. Am J Med 2A:25-34, 1988
37. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (London) New Biol 231:232-235, 1971
38. Redfern JS, Feldman M: Role of endogenous prostaglandins in preventing gastrointestinal ulceration: Induction of ulcers by antibodies to prostaglandins. Gastroenterology 96:596-605, 1989
39. Wallace JL: Non-steroidal anti-inflammatory gastropathy and cytoprotection: Pathogenesis and mechanisms re-examined. Scand J Gastroenterol 27(suppl 192):3-8, 1992
40. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89:7384-7388, 1992
41. Vane J: Towards a better aspirin. Nature 367:215-216, 1994
42. Simon LS: Nonsteroidal antiinflammatory drugs and their effects: The importance of COX "selectivity." J Clin Rheumatol 2:135-140, 1996
43. Robert A, Nezamis JE, Phillips JP: Inhibition of gastric secretion by prostaglandins. Am J Dig Dis 12:1073-1076, 1967
44. Collins PW: Misoprostol: Discovery, development, and clinical applications. Med Res Rev 10:149-172, 1990
45. Cohen MM, Clark L, Armstrong L, D'Souza J: Reduction of aspirin-induced fecal blood loss with low-dose misoprostol tablets in man. Dig Dis Sci 30:605-611, 1985
46. Ryan JR, Vargas R, Clay GA, McMahon FG: Role of misoprostol in reducing aspirin-induced gastrointestinal blood loss in arthritic patients. Am J Med 83(suppl 1A):41-44, 1987
47. 2: An endoscopie study. Gastroenterology 86:339-345, 1984
48. Silverstein FE, Kimmey MB, Saunders DR, Levine DS: Gastric protection by misoprostol against 1300 mg aspirin: An endoscopic study. Dig Dis Sci 31:137S-141S, 1986
49. Silverstein FE, Kimmey MB, Saunders DR, Levine DS: Gastric protection by misoprostol against 1,300 mg of aspirin: An endoscopic dose-response study. Am J Med 83(suppl 1A):32-36, 1987
50. Jiranek GC, Kimmey MB, Saunders DR, et al: Misoprostol reduces gastroduodenal injury from one week of aspirin: An endoscopie study. Gastroenterology 96:656-661, 1989
51. Lanza FL: A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Br J Clin Pract 00:(May suppl):95-101, 1987
52. Lanza FL, Fakaouhi D, Rubin A, et al: A double-blind, placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 meg of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms. Am J Gastroenterol 84:633-636, 1989
53. Aadland E, Fausa O, Vatn M, et al: Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med 83(suppl 1A):37-40, 1987
54. Graham DY, White RH, Moreland LW, et al: Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 119:257-262, 1993
55. Elliott SL, Yeomans ND, Buchanan RR, Smallwood RA: Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial. Scand J Rheumatol 23:171-176, 1994
56. Agrawal NM, Van Kerckhove HE, Erhardt LJ, Geis GS: Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci 40:1125-1131, 1995
57. Taha AS, Hudson N, Trye P, et al: Prevention of NSAID-related gastric and duodenal ulcers by famotidine. A placebo-controlled double-blind study. Gastroenterology 106:A190, 1994
58. Simon TJ, Berger ML, Hoover ME, et al: Famotidine for the prevention of gastric and duodenal ulcers associated with nonsteroidal antiinflammatory drugs. Am J Gastroenterol 89:1644, 1994 (abstract)
59. Oddsson E, Gudjonsson H, Thjodleifsson B: Protective effect of omeprazole or ranitidine against naproxen-induced damage to the human gastroduodenal mucosa. Scand J Gastroenterol 25(suppl 176):13, 1990 (abstract)
60. Scheiman JM, Behler EM, Loeffler KM, Elta GH: Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 39:97-103, 1994
61. Ekström P, Carling L, Wetterhus S, Wingren PE, Naesdal J, Lamm M: Omeprazole reduces the frequency of gastroduodenal lesions and dyspeptic symptoms during NSAID treatment. Gastroenterology 108:A87, 1995 (abstract)
62. Cullen D, Bardhan KD, Eisner M, et al: Primary gastroduodenal prophylaxis with omeprazole for NSAID users. Gastroenterology 110(4):A86, 1996
63. Hawkey CJ, Swannell AJ, Eriksson S, et al: Lower frequency of gastroduodenal ulcers and erosions and dyspeptic symptoms in NSAID users during maintenance with omeprazole compared with ranitidine. Gastroenterology 110(4):A131, 1996
64. Yeomans ND, Swannell AJ, Walan A, Lamm M, Naesdal J, Hawkey CJ: Direct comparison of omeprazole and misoprostol as maintenance treatment for NSAID-associated gastroduodenal ulcers, erosions, and symptoms. Rheumatol Eur 25 (Suppl): A232, 1996 (abstract)
65. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, Lamers CB: Achlorhydria does not protect against upper gastrointestinal ulcers during NSAID use. Dig Dis Sci 39:362-365, 1994
66. Walt RP: Misoprostol for the treatment of peptic ulcer and antiinflammatory drug-induced gastroduodenal ulceration. N Engl J Med 327:1575-1580, 1992
67. Silverstein FE, Graham DY, Senior JR, et al: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:241-249, 1995
68. Geis GS, Stead H, Wallemark CB. et al: Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol 18(suppl 28):11-14, 1991
69. Medical Research Council Working Party: MRC trial of treatment of mild hypertension. BMJ 291:97-104, 1985
70. Lipid Research Clinics Program: The Lipid Research Clinics coronary primary prevention trial results. JAMA 251:351-374, 1984
71. Avorn JU, Solomon D, Levin R, Lo J: Epidemiologic analysis of prophylactic drug use and NSAID gastropathy. Arthritis Rheum 39(suppl):S185, 1996 (abstract 827)
72. Simon LS, Polisson RP, Hatoum HT, Bittman RM: Risk factors for serious nonsteroidal induced GI complications: The risk reduction effect of misoprostol therapy in the individual "at-risk" patient. Arthritis Rheum 38(suppl):S206, 1995
73. Gabriel SE, Jaakkimainen RL, Bombardier C: The cost-effectiveness of misoprostol for nonsteroidal anti-inflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 36:447-459, 1993
74. Raskin JB, White RH, Jackson JE, et al: Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens. Ann Intern Med 123:344-350, 1995
75. Melo Gomes JA, Roth SH, Zeeh J, Bruyn GAW, Woods EM, Geis GS: Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 52:881-885, 1993
76. Murray MD, Birt JA, Manatunga AK, Darnell JC: Medication compliance in elderly outpatients using twice-daily dosing and unit-of-use packaging. Ann Pharmacother 27:616-621, 1993
77. Kirchner JT: Nonsteroidal anti-inflammatory drug use in the elderly. J Am Osteopath Assoc 94:300-304, 1994
78. Salzman C: Medication compliance in the elderly. J Clin Psychiatry 56(suppl 1):18-22, 1995
79. Hannequin JR: Efficacy of Arthrotcc in the treatment of rheumatoid arthritis. Scand J Rheumatol 21(suppl 96):7-14, 1992
80. Doherty M: The efficacy of Arthrotec in the treatment of osteoarthritis. Scand J Rheumatol 21(suppl 96):15-21, 1992
81. Bolten W, Melo Gomes JA, Stead H, Geis GS: The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 31:753-758, 1992
82. Verdickt W, Moran C, Hantzschel H, Fraga AM, Stead H, Geis GS: A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 21:85-91, 1992